证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-099 江苏恒瑞医药股份有限公司 关于获得药品注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司成都盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）的通知，批准 公司产品全氟己基辛烷滴眼液上市，用于治疗睑板腺功能障碍（MGD）相关干眼。 现将相关情况公告如下： 一、药品的基本情况 药品名称：全氟己基辛烷滴眼液（SHR8058） 剂型：眼用制剂 规格：3ml 注册分类：参照 3 类仿制药 受理号：CXHS2300021 批准的适应症：本品用于治疗睑板腺功能障碍相关干眼。 二、药品的其他情况 《中国干眼临床诊疗指南（2023 年）》[1]提到，我国干眼的发病率为 21%-30%。 一项临床研究结果显示[2,3]，69%-86%的干眼人群患有 MGD。这表明在治疗干眼病 时，针对睑板腺功能障碍的治疗显得尤为重要。根据《中国睑板腺功能障碍专家 共识：诊断和治疗（2023 年）》[4 ...

上 半 年 ， A 股 IPO 募 集 总 额 达 373.55 亿 元 ， 同 比 增 长 14.96%； 港 股 IPO 融 资 规 模 达 974.25 亿 元 ， 同 比 激 增 688.56%。 作者： 牛钰 封图：图虫创意 从年初的"松动"信号到年中节点，IPO（首次公开发行）市场节奏和主线的变化一直牵动着资本市 场的神经。回头来看，在政策优化和市场复苏的双向加持下，2025年IPO市场的活跃度骤起，融资 项目与规模显著回暖。 Wind数据显示，截至6月30日，上半年A股共有51只新股上市，同比增加7家，IPO募集总额达 373.55亿元，同比增长14.96%。其中，9只新股募资金额超过10亿元，中策橡胶（603049.SH）首 发募资金额最高，达40.66亿元。 港股IPO市场更是火热"出圈"，上半年共有43家企业成功上市，IPO融资规模达1067.13亿港元（约 合人民币974.25亿元），同比激增688.56%。按交易所排名，港交所的IPO融资规模位居全球榜 首，居于其后的纳斯达克交易所在上半年有79宗IPO（剔除特殊目的收购公司），筹资约90.74亿 美元（约合人民币650.32亿元）。 ...

经济观察报记者 邹永勤 近日，创新药领域政策不断。 为进一步完善全链条支持创新药发展举措，推动创新药高质量发展，2025年6月30日，国家医保局、国家卫生健康委联合对外印发《支持创新药高质量发展 的若干措施》（下称《若干措施》）。 紧接着7月1日，国家医保局根据《若干措施》的要求，研究起草了《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录 调整工作方案（征求意见稿）》等文件，并向社会公开征求意见。 对此，浙江盛元私募基金管理有限公司合伙人郭永智向记者表示，近年来一系列相关扶持政策的出炉，很好地构建了支持创新药高质量发展的闭环体系，从 而有力促进了我国从 "创新药大国" 向"创新药强国"的转型。 创新药扶持政策连续加码 "此次《若干措施》的出炉，是对过往一系列创新药扶持政策在连贯性方面的进一步强化。"郭永智在接受记者采访时说。 郭永智是暨南大学药理学博士，目前在基金公司主要负责生物医疗大健康的投资，对创新药领域有着长期的跟踪研究。据他介绍，自2019年百济神州的泽布 替尼在美国成功获批实现零的突破后，中国创新药企业的出海授权金额不断激增、全球化进程明显加快，加上AI制药技术不断 ...

富时中国A50指数连续 金十图示：2025年07月03日（周四）富时中国A50指数成分股今日收盘行情一览：证券、消费电子、家电等板块收高，石油、煤 炭等板块收低，银行、保险等板块涨跌不一 -0.01(-0.18%) +0.06(+0.71%) +0.03(+0.71%) 保险 中国太保 中国平安 12,000 中国人保 电机 3825.38亿市值 3573.96亿市值 10161.31亿市值 5.06亿成交额 18.17亿成交额 6.14亿成交额 55.80 37.15 8.65 +0.03(+0.08%) -0.01(-0.02%) -0.04(-0.46%) 酸酒行业 贵州茅台 五粮液 山内对酒 17782.74亿市值 2142.50亿市值 4643.18亿市值 34.57亿成交额 10.02亿成交额 14.64亿成交额 1415.60 175.62 119.62 +6.00(+0.43%) 0.00(0.00%) +0.44(+0.37%) 术学体 北方华创 寒武纪-U 海光信息 HYGON 2368.09亿市值 2289.63亿市值 3146.22亿市值 13.25亿成交额 21.74亿成交额 12. ...

Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock C fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of July 2, 2025, the latest net value of ICBC Frontier Medical Stock C is 2.9870 yuan, reflecting a decrease of 2.48% [1] - The fund's performance over the past month shows a return of -0.53%, ranking 804 out of 898 in its category; over the past six months, it has achieved a return of 18.53%, ranking 133 out of 878; and since the beginning of the year, it has returned 16.32%, ranking 134 out of 878 [1] Group 2 - The top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] - The fund was established on November 23, 2020, and as of March 31, 2025, it has a total scale of 1.38 billion yuan, managed by fund manager Zhao Bei [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 江蘇恒瑞醫藥股份有限公司 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 224,519,800 | RMB | | 1 RMB | | 224,519,800 | | 增加 / 減少 (-) | | | 33,677,800 | | | RMB | | 33,677,800 | | 本月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 2. ...

金十图示：2025年07月02日（周三）富时中国A50指数成分股今日收盘行情一览：家电、白酒、有色金属等板块收高，证券、消 费电子、物流等板块收低 富时中国A50指数连续 0.00(0.00%) -0.09(-1.05%) +0.02(+0.48%) 保险 中国太保 12.00 中国人保 中国平安 电机 3843.06亿市值 3571.07亿市值 10163.13亿市值 5.73亿成交额 22.04亿成交额 4.55亿成交额 55.81 37.12 8.69 -0.29(-0.78%) +0.11(+0.20%) -0.02(-0.23%) 酸酒行业 贵州茅台 五粮液 山内对酒 17707.36亿市值 2142.50亿市值 4626.10亿市值 36.89亿成交额 11.55亿成交额 18.41亿成交额 119.18 175.62 1409.60 +4.50(+0.32%) +1.20(+0.69%) +0.55(+0.46%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2280.43亿市值 2336.50亿市值 3150.87亿市值 13.00亿成交额 35.10亿成交额 13.95亿成交额 13 ...

Group 1 - The core viewpoint is that the Hong Kong IPO market has experienced a significant surge in activity this year, with 27 companies successfully listed and total fundraising exceeding 77 billion HKD by May 28, approaching last year's total [1] - Notable IPOs include the successful listing of Mixue Group, which raised 1.77 trillion HKD, and CATL's listing that raised over 35 billion HKD, making it the second-largest IPO globally after Saudi Aramco [1] - There are currently 157 companies waiting to go public in Hong Kong, with 18 projects seeking to raise over 5 billion HKD [1] Group 2 - The surge in Hong Kong IPOs is attributed to a combination of policy support, improved market conditions, and strategic moves by companies [2] - The Hong Kong Stock Exchange has optimized listing regulations, including the introduction of the "Specialized Technology and Biotech Companies" route, which lowers the listing threshold for early-stage tech firms [2] - The China Securities Regulatory Commission has implemented measures to support mainland companies listing in Hong Kong, reducing the review time from 100 days to 60 days [2] Group 3 - The improvement in liquidity in the Hong Kong market has been a key support for the ongoing IPO activity, with net inflows from southbound funds exceeding 600 billion HKD since last year [2] - The average daily trading volume in Hong Kong has increased to over 240 billion HKD this year, nearly doubling from the previous year [2] - Hong Kong has become a hub for scarce technology and consumer stocks, with over 80% of the MSCI index comprising Hong Kong stocks, indicating a sustained trend of foreign capital inflow [2] Group 4 - Chinese companies are accelerating their internationalization, with Hong Kong serving as a crucial platform for global financing amid increasing domestic competition and international headwinds [3] - Companies are utilizing the Hong Kong platform to raise offshore funds for overseas expansion, brand acquisitions, and supply chain development, exemplified by CATL's fundraising for its Hungarian factory [3] - The IPO environment is improving, leading to a structural upgrade in the supply of quality assets in Hong Kong, attracting long-term capital allocation [3]

占据全球总量24%，超越纳斯达克与纽交所 羊城晚报全媒体记者 胡彦 根据Wind数据及港交所公开信息统计，截至今年6月30日，港股市场上半年共有43只新股成功上市，较2024年同期的30家增长43.3%；首发募集资金总额高 达1067.14亿港元（约合人民币980亿元），这一数字超过2024年全年的876.77亿港元，同时也创下自2022年以来的三年新高。按交易所排名，港交所IPO募 资规模稳居全球第一。 在行业分布方面，"新消费+硬科技"行业成为一大引擎。上半年，生物科技与健康、零售和消费两大行业的IPO数量并列第一。 "A+H"热潮持续升温。"A+H"上市模式是指企业既在中国内地的A股市场发行上市，又在中国香港的H股市场发行上市，实现同时在两地挂牌交易。Wind数 据显示，今年已有赤峰黄金、钧达股份、宁德时代、恒瑞医药、吉宏股份、海天味业、三花智控等A股企业登陆港股。截至6月25日，全市场已有151 家"A+H"上市公司。 其中，宁德时代、恒瑞医药、海天味业占据上半年港股IPO募资金额的前三，分别募资410.1亿港元、113.7亿港元、101.3亿港元，合计625.1亿港元，占募资 总额的58.6%。动力 ...

Group 1 - The core viewpoint of the articles highlights the increasing support and favorable policies for the innovative drug sector in China, indicating a significant growth phase for the industry [1][2] - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including 16 specific actions [1] - The China innovative drug industry has seen breakthroughs this year, with multiple innovative drugs approved for market entry and increased international collaboration, suggesting a strong potential for investment in the pharmaceutical sector by 2025 [1][2] Group 2 - According to a report from招商证券, over 80 innovative drug projects have completed business development (BD) transactions in China as of June 2023, with the upfront payment for these transactions increasing from $500 million in 2020 to $4.1 billion in 2024 [1][2] - The innovative drug index has risen over 26% this year, with average gains of 35% for innovative drug concept stocks, significantly outperforming the Shanghai Composite Index [2] - Specific companies like 泰恩康 and 舒泰神 have shown remarkable stock performance, with 泰恩康's stock up 146.29% and 舒泰神's stock increasing nearly fivefold this year [2] Group 3 - Market enthusiasm for the innovative drug sector is high, with many concept stocks receiving significant institutional research attention, including companies like 健康元 and 皓元医药 [3] - 皓元医药 reported a more than 30% year-on-year increase in its order volume for innovative drug intermediates and raw materials as of Q1 2025 [3] - Companies like 科兴制药 are planning to expand their international market presence, with a target of increasing overseas sales by 200% to 400% compared to 2023 by 2025 [3] Group 4 - 恒瑞医药 has received the highest institutional attention among innovative drug stocks, with 25 institutions giving it an "active" rating [4] - Other companies such as 康龙化成 and 华东医药 also have high levels of institutional interest, indicating a strong market focus on these innovative drug firms [4]